Skip to main content
Uncategorized

Advancell signs an agreement with the biotech Solvo to launch a new reagent

By 11 de March de 2010November 18th, 2020No Comments
< Back to news
 11.03.2010

Advancell signs an agreement with the biotech Solvo to launch a new reagent

The biotech company Advancell, with headquarters at the Barcelona Science Park, has just signed an agreement with the Hungarian biotech Solvo, in order to commercialize a family of cell reagents, PreadyPortTM, which will be presented in Munich next April 8. Advancell has committed to contributing its knowledge and technology to reagents by means of its ready-to-use system, and Solvo to providing its knowhow of cell transporters.The first reagent, PreadyPortTm-MDR1, will enable the search for specific substrates of the MDR-1 transporter (resistance gene to multiple drugs), the detection of its inhibitors and the observation of the interaction of several compounds with each other, with the aim of understanding and improving the therapeutic use of certain drugs.

Additionally, the use of the reagent in the first phase of drug development will help large pharmaceutical companies save time and costs in standard substance analysis procedures that are carried out in laboratories, given that in vitro technology enables researchers to determine whether a compound is efficacious or not in early stages, and those that are not effective are immediately discarded. The commercialization of the reagent will be jointly carried out at each company’s corresponding markets. After its commercialization in Europe and in the United States, it will be commercialized in Asia in a second phase.

Advancell is a leading biotech company in the research of nanomedicine and cell methods for in vitro research that offers solutions to unresolved health and wellbeing needs by providing efficient products and services that have an added value. The company is nurtured by academic findings to improve, develop and license these products to third parties or to introduce them into the market. The biotech Solvo is a Hungarian company created by a group of scientists in 1999. It has two laboratories in Hungary and over 60 employees. Solvo is a pioneer in the commercialization of membrane transporter-based technologies.